SecBot SecBot
PRESS-RELEASE ·Filed Aug 28, 2026

TEVA

Teva Pharmaceutical Industries Ltd
BULLISH
Impact 6/10
Horizonmonths Processed2mo ago WireGlobeNewswire
Press release · M&A
Actionable Insight ▲ Bullish

Monitor the bankruptcy court auction for competing bids and the November 14, 2026 PDUFA date for FDA approval. If approved, IGALMI could become a meaningful new revenue stream for Teva's neuroscience portfolio, but the deal is not yet final and carries execution risk.

DirectionBullish
Confidencemedium
Horizonmonths

BXCL-501

● Neutral Named in this press release
Impact
Phase
Approved (in-hospital); sNDA under FDA review for at-home use
Time to market
Already approved as IGALMI for in-hospital use. The at-home label expansion decision is due by November 14, 2026 PDUFA date. If approved, commercial launch for at-home use would follow shortly after, led by Teva.
Next catalyst
None dated

What to watchThe PDUFA decision on November 14, 2026 is the key catalyst. An approval would validate Teva's $57.5M acquisition and open a first-to-market at-home agitation market. A CRL would be a setback but not devastating for Teva given its diversified portfolio. Watch for any FDA AdComm announcement or pre-PDUFA news flow in the coming days.

How the stock moved after the report

BULLISH VIEWSTOCK ABOVE ENTRY AT T+20
Entry
$36.44
T+0 close · Aug 28, 2026 · via day close
Latest settled
+7.55%
T+20 · $39.19 · next T+60 in 6d
Vs SPY
+7.04%
α at T+20
Latest observation
+29.05%
T+54 · FF3 residual α
  1. T+0 · Aug 28 $36.44entry
  2. T+1 · 3mo ago −1.07%α −0.77% · $36.05
  3. T+5 · 2mo ago −0.22%α −0.33% · $36.36
  4. T+20 · 7w ago +7.55%α +7.04% · $39.19
  5. T+55 · todayOpen
  6. T+60 · in 6d Pending
Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

Teva announced a stalking-horse bid to acquire BioXcel Therapeutics' IGALMI (dexmedetomidine sublingual film) and related assets for $57.5M upfront plus up to $67.5M in contingent payments, through a court-supervised bankruptcy sale. The asset is under FDA review for at-home use in agitation associated with schizophrenia or bipolar disorder, with a PDUFA date of November 14, 2026. If approved, this would be the first FDA-approved at-home treatment for this condition, expanding Teva's psychiatry portfolio.

Key Financial Metrics

Deal Value
$57.5M

Key Facts

  • Teva is the stalking-horse bidder for BioXcel Therapeutics' IGALMI (dexmedetomidine sublingual film) in a Section 363 bankruptcy sale.
  • Upfront payment of $57.5 million plus up to $67.5 million in contingent payments tied to FDA approval timing and sales milestones.
  • PDUFA target action date for at-home use approval is November 14, 2026.
  • If approved, IGALMI would be the first FDA-approved at-home treatment for agitation associated with schizophrenia or bipolar I/II disorder.
  • Transaction remains subject to bankruptcy court approval, potential higher bids, and customary closing conditions.
  • Teva would receive a break-up fee and expense reimbursement if not the successful bidder.

Financial Impact

Up to $125 million total consideration ($57.5M upfront + $67.5M contingent), with potential for significant upside if approved and commercialized.

revenuedebtdilution

Risk Factors

  • Bankruptcy court may approve a higher bid from another party.
  • FDA may not approve the at-home use indication by the PDUFA date or at all.
  • Contingent payments depend on approval timing and sales milestones, which are uncertain.
  • Integration and commercialization risks if the deal closes.

Market Snapshot

Exchange
OTC
Sector
Pharmaceutical Preparations
Analyst Consensus
86% bullish (7 analysts)

Investment Themes

Documents Analyzed

This report is based on 1 press release from GlobeNewswire.

DocumentAccession Number
PRESS-RELEASE Data (Synthetic)press-3352601

Track record

61 reports on TEVA

Performance horizon

6 of 8 bullish or bearish reports moved the stock their way by T+60. Best: +33.06% at T+60 after the Jul 20, 2026 report. 14 of 16 went positive at some point.

Filters
  1. Nov 16, 2026today SC 13G/A Neutral 2/10 Entry $43.16 Now $44.50 +3.10% settles Feb 12
  2. Nov 12, 20264d ago 3 Neutral 2/10 Entry $44.50 Now $44.50 0.00% settles Feb 11
  3. Nov 12, 20264d ago 144 Neutral 2/10 Entry $44.50 Now $44.50 0.00% settles Feb 11
  4. Nov 12, 20264d ago 144 Neutral 2/10 Entry $43.65 Now $44.50 +1.95% settles Feb 10
  5. Nov 10, 20266d ago 144 Neutral 3/10 Entry $43.24 Now $44.50 +2.91% settles Feb 9
  6. Nov 10, 20266d ago SC 13G/A Neutral 3/10 Entry $42.40 Now $44.50 +4.95% settles Feb 8
  7. Nov 9, 20267d ago 144 Neutral 2/10 Entry $42.40 Now $44.50 +4.95% settles Feb 8
  8. Nov 6, 202610d ago Insider Cluster Neutral 3/10 Entry $42.97 Now $44.50 +3.56% settles Feb 5
  9. Nov 6, 202610d ago Insider Cluster Neutral 2/10 Entry $42.97 Now $44.50 +3.56% settles Feb 5
  10. Nov 5, 202611d ago 144 Neutral 2/10 Entry $42.61 Now $44.50 +4.44% settles Feb 4
Showing 10 of 61

US Market Status

Market Closed · Opens Wed (11h 56m)

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Aug 28, 2026